Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY24 results · Oct–Dec 2023
Bliss GVS Pharma reported revenue from operations of ₹200.72 crore (down 2.4% from Q3 FY23) and net profit of ₹29.07 crore (down 2.4% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.72 | 205.72 | −2.4% | 211.88 | −5.3% |
| Other income | 5.42 | 5.65 | −4.0% | 12.60 | −57.0% |
| Total income | 206.14 | 211.36 | −2.5% | 224.48 | −8.2% |
| Profit before tax | 40.04 | 47.43 | −15.6% | 59.13 | −32.3% |
| Net profit for the period | 29.07 | 29.79 | −2.4% | 43.04 | −32.5% |
| Attributable to shareholders of the company | 27.61 | 27.94 | −1.2% | 42.31 | −34.7% |
| EPS, basic (₹) | 2.64 | 2.68 | −1.5% | 4.06 | −35.0% |
| Net margin (%) | 14.5 | 14.5 | 20.3 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 161.33 | 168.79 | −4.4% | 171.32 | −5.8% |
| Other income | 7.90 | 11.42 | −30.9% | 10.61 | −25.6% |
| Total income | 169.23 | 180.21 | −6.1% | 181.93 | −7.0% |
| Profit before tax | 28.52 | 39.89 | −28.5% | 46.07 | −38.1% |
| Net profit for the period | 20.72 | 29.28 | −29.2% | 33.89 | −38.9% |
| EPS, basic (₹) | 1.99 | 2.81 | −29.2% | 3.25 | −38.8% |
| Net margin (%) | 12.8 | 17.3 | 19.8 |
Consolidated
- Filed with BSE
- 02 Feb 2024, 18:59 IST
- Board meeting
- 23 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Feb 2024, 18:59 IST
- Board meeting
- 23 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE